About Blincyto: The blincyto injection contains blinatumomab as an active pharmaceutical ingredient (API). It falls under the group of drugs named antineoplastic agents which is involved in order to target the cancerous cells.
Indication: Blincyto (Blinatumomab) is used to treat adult patients with acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia is a cancer of the blood in which white blood cell named “B-lymphocyte” is growing out of control. This medication works by enabling the immune system to attack and kills abnormal WBCs. The blincyto injection is used when ALL has come back or has not responded to last treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia). This medicine is also used in adults with acute lymphoblastic leukaemia who still have a small number of cancer cells left after last treatment (referred to as minimal residual disease).
This medication is used for thetreatment of children (≥ 1 year old), teenagers and young adults with acutelymphoblastic leukaemia (ALL) when lat treatments was not effective or have stopped working.
Dosage & Administration: Always use blincyto dose exactly as your healthcare professional have told you. This medicine will be given to you through a vein (intravenous) continuously for four weeks using an infusion pump (this is 1 treatment cycle). You will then have a two week off where you will not be administered the infusion. Your infusion catheter will be attached to you at all times during each cycle of your treatment.
Blincyto (Blinatumomab) is usually given for 2 treatment cycles in case you have relapsed or refractory acute lymphoblastic leukaemia, or for one treatment cycle in case you've minimal residual disease ALL. In case you respond to this therapy, your healthcare professional may determine to give you up to 3 additional cycles of therapy. The number of treatment cycles and the blinatumomab dose which you will be administered will depend on how you tolerate and respond to therapy. Your healthcare team will discuss with you how long your therapy be will the last. In paediatric patients with high risk first relapse of ALL (Acute Lymphoblastic Leukaemia), this medication will be given for 1 treatment cycle. Your blinatumomab therapy may also be interrupted depending on how you tolerate to this medication.
Possible Side Effects: The blinatumomab injection may cause be responsible for causing serious side effects, including:
Infections: Blinatumomab may cause severe or life-threatening infections that may lead to death. Report your doctor immediately if you develop any signs/symptoms of an infection.
Low WBC counts (Neutropenia): Neutropenia is common with Blinatumomab therapy and may be life-threatening. Low WBC counts can increase your risk of getting an infection. Your doctor will perform your blood tests in order to assess your WBC count during treatment with Blinatumomab. Report your healthcare professional promptly in case you get a fever.
Abnormal liver blood tests: Your healthcare professional will perform blood tests in order to assess your liver prior to starting and during therapy with Blinatumomab.
Inflammation of the pancreas (pancreatitis): Inflammation of the pancreas may happen in recipients treated with this medication and corticosteroids. It could be severe and lead to death. Report your doctor promptly in case you have severe and persistent stomach-area pain. The pain may happen either with or without nausea and vomiting.
The most commonly reported side effects of Blinatumomab include fever, headache, low red blood cell count (anemia), infections, low platelet count (thrombocytopenia). It may also cause reactions related to infusion of the drug such as low blood pressure, face swelling, and high blood pressure.
Overdose: In case of blinatumomab overdose, seek emergency medical attention or call your healthcare professional team.
Missed Dose: Patients are advised to contact their healthcare providers in case they miss an appointment for their blinatumomab injection.
Storage: Do not open the Intravenous bags containing blincyto infusion. Do not freeze the package. The blincyto package will be opened by your doctor and stored in the refrigerator at temperature 36°F to 46°F (2°C to 8°C) for up to 8 days. Avoid throwing away (disposing of) any blinatumomab in the household trash. Discuss with your doctor about Blincyto disposal and used supplies.
Price: The blinatumomab price in India can vary. To know the best price of blinatumomab, kindly get in touch with us today at our TOLL-FREE Number: 1800-889-1064.
Note: The information provided in this article named "Blincyto: Information for the Patient", is only for informational purposes and is not served as a substitute for the medical treatment, consultation, diagnosis, of a qualified healthcare professional.
